SCHEMBL6089480

SCHEMBL6089480

Cc1ccc(C2NC(=O)c3cccc4c3N2CCC4=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 3/20 0.42
HTR2C P28335 3/20 0.41
HTR2B P41595 3/20 0.41
KDM4E B2RXH2 7/20 0.38
ALDH1A1 P00352 5/20 0.38
GAA P10253 2/20 0.38
POLB P06746 1/20 0.38
MAOB P27338 1/20 0.36
HPGD P15428 4/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HSD17B10 Q99714 2/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
CASP1 P29466 1/20 0.35
BLM P54132 1/20 0.35
CASP7 P55210 1/20 0.35
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090523 0.88 TNKS2 (0.39) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6089877 0.87 PARP1 (0.39) HTR2CHTR2BKDM4EALDH1A1POLB
SCHEMBL6091873 0.87 MEN1 (0.42) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6090229 0.86 ALDH1A1 (0.41) HTR2CHTR2BKDM4EALDH1A1GAA
SCHEMBL6092226 0.86 TNKS2 (0.45) TNKS2KDM4EALDH1A1GAAMAOB
SCHEMBL6090498 0.84 TNKS2 (0.38) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6090492 0.84 TNKS2 (0.38) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6090894 0.84 ATM (0.41) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6091636 0.84 PARP1 (0.40) TNKS2HTR2CHTR2BKDM4EALDH1A1
SCHEMBL6089133 0.84 HTR2C (0.36) HTR2CHTR2BKDM4EALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 TNKS2 15/4885HTR2C 3206/4885HTR2B 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.